ERECTILE DYSFUNCTION AND ITS PHARMACOLOGY: AN OVERVIEW
It has been estimated that currently over 150 million men worldwide suffer from erectile dysfunction (ED) and by 2025, the figure will increase beyond 322 millions. ED is the inability to achieve, and/or maintain penile erection sufficient for satisfactory sexual intercourse, and was previously regarded as the part of aging. It is associated with certain diseases and life style habits with a cause-effect relationship, including diabetes mellitus, hypertension, dyslipidemia, and cigarette smoking. Internationally, most of the men with ED fail to pursue treatment due to the complex nature of sexuality, taboos, cultural restrictions, and acceptance of ED as a normal sequel of aging. In this review, we discussed the physiology, diagnosis, and risk factors associated with ED and current treatment strategies for ED.
Keywords: Erectile dysfunction, Diabetes, Penile erection, Phosphodiesterase inhibitors.
2. Halvorsen JG, Metz ME. Sexual dysfunction, Part I: Classification, etiology, and pathogenesis. J Am Board Fam Pract 1992;5(1):51-61.
3. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB.
The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60(4):458-65.
4. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999;161(1):5-11.
5. De Leo D, Magni G. Sexual side effects of antidepressant drugs.
6. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12 Suppl 4:S6-11.
7. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH.
Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: From the male attitudes regarding sexual health survey. J Sex Med 2007;4(1):57-65.
8. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev
9. Andersson KE. Pharmacology of penile erection. Pharmacol Rev
10. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. Pharmacol Ther 2006;111(2):400-23.
11. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in
2869 men using a validated questionnaire. Eur Urol 2005;47(1):80-5.
12. Saenz de Tejada I, Carson MP, de las Morenas A, Goldstein I, Traish AM. Endothelin: Localization, synthesis activity and receptor types in human penile corpus cavernosum. Am J Physiol 1991;261:H1078-85.
13. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, et al. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts male aging study. Prev Med
14. Chung WS, Sohn JH, Park YY. Is obesity an underlying factor in erectile dysfunction? Eur Urol 1999;36(1):68-70.
15. Mikhailidis DP, Ganotakis ES, Papadakis JA, Jeremy JY. Smoking and urological disease. J R Soc Promot Health 1998;118(4):210-2.
16. Ledda A. Cigarette smoking, hypertension and erectile dysfunction.
Curr Med Res Opin 2000;16 Suppl 1:s13-6.
17. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338(20):1397-404.
18. Moncada I, Jara J, SubirÃ¡ D, CastaÃ±o I, HernÃ¡ndez C. Efficacy of sildenafil citrate at 12 hours after dosing: Re-exploring the therapeutic window. Eur Urol 2004;46(3):357-60.
19. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-6.
20. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R.
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology
21. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase Type 5 inhibitor, in men with erectile dysfunction: Results of a randomized, doubleblind, 26-week placebo-controlled pivotal trial. Urology 2003;61 4 Suppl 1:8-14.
22. Bischoff E, Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 2001;13(4):230-5.
23. Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction.
Endocrinol Metab Clin North Am 2007;36(2):465-79.
24. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Urol
Clin North Am 2005;32(4):397-402, v.
25. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: New guidelines for sexual medicine. J Sex Med 2006;3(1):28-36.
26. Zhang X, Feng Q, Cote RH. Efficacy and selectivity of phosphodiesterase- targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci 2005;46(9):3060-6.
27. Dula E, Bukofzer S, Perdok R, George M; Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39(5):558-3.
28. Goldstein I, Payton TR, Schechter PJ. A double-blind, placebo- controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology 2001;57(2):301-5.
29. Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol 1993;149(2):290-4.
30. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol 1996;155(5):1609-12.
31. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am
32. Hellstrom WJ, Bennett AH, Gesundheit N, Kaiser FE, Lue TF, Padma-Nathan H, et al. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology
33. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336(1):1-7.
34. Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama Ã Nijeholt GA, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol 1998;81(6):889-94.
35. Bodner DR, Haas CA, Krueger B, Seftel AD. Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury. Urology 1999;53(1):199-202.
36. Lewis RW. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction. Int J Impot Res
37. Traish AM, Goldstein I, Kim NN. Testosterone and erectile function: From basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction. Eur Urol
38. Saleh DO, El-Awdan SA, Nofel SM, El-Eraky WI, El-Khatib AS, Kenawy SA. Estrogens improve the cardiovascular alterations in fructose-induced insulin resistant ovariectomized rats. Int J Pharm Pharm Sci 2015;7(7):241-7.
39. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: Results of a meta-analysis. J Urol
40. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172(2):658-63.
41. Mulcahy JJ, Austoni E, Barada JH, Choi HK, Hellstrom WJ, Krishnamurti S, et al. The penile implant for erectile dysfunction. J Sex Med 2004;1(1):98-109.
42. Wilson S, Delk JR 2nd, Henry GD, Siegel AL. New surgical technique for sphincter urinary control system using upper transverse scrotal incision. J Urol 2003;169(1):261-4.
43. Lee JH, Cho SH, Kim JY, Park HJ, Do JA, Baek S. Determination and quantification of nine adulterant local anaesthetics in illegal treatments for male premature ejaculation by GC-FID and GC-MS. Int J Pharm Pharm Sci 2016;8(3):135-40.
44. Montorsi F, Rigatti P, Carmignani G, Corbu C, Campo B, Ordesi G, et al. AMS three-piece inflatable implants for erectile dysfunction: A long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000;37(1):50-5.
45. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB.
Impotence and its medical and psychosocial correlates: Results of the
Massachusetts Male Aging Study. J Urol 1994;151(1):54-61.
46. Reiter WJ, Pycha A, Schatzl G, Pokorny A, Gruber DM, Huber JC, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: A prospective, double-blind, randomized, placebo-controlled study. Urology 1999;53(3):590-4.
47. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol
48. Guirguis WR. Oral treatment of erectile dysfunction: From herbal remedies to designer drugs. J Sex Marital Ther 1998;24(2):69-73.
49. Zaher TF. Papaverine plus prostaglandin E1 versus prostaglandin
E1 alone for intracorporeal injection therapy. Int Urol Nephrol
50. Junemann KP, Alken P. Pharmacotherapy of erectile-dysfunction. Int J Impot Res 1989;1:71-93.
51. Adimoelja A. Phytochemicals and the breakthrough of traditional herbs in the management of sexual dysfunctions. Int J Androl
2000;23 Suppl 2:82-4.
52. Adaikan PG, Gauthaman K, Prasad RN, Ng SC. Proerectile pharmacological effects of Tribulus terrestris extract on the rabbit corpus cavernosum. Ann Acad Med Singapore 2000;29(1):22-6.
53. Choudhary I, Ur-Rahman A. Elixirs of love. Chem Br 1997;33:25-7.
54. Choi HK, Seong DH, Rha KH. Chemical efficiency of Korean red ginseng for erectile-dysfunction. Int J Impot Res 1995;7(3):181-6.
55. Muhammad I, Zhao J, Dunbar DC, Khan IA. Constituents of Lepidium meyenii â€˜macaâ€™. Phytochemistry 2002;59(1):105-10.
56. Ang HH, Sim MK. Eurycoma longifolia JACK and orientation activities in sexually experienced male rats. Biol Pharm Bull 1998;21(2):153-5.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.